Udine, Italy
Joined March 2020
Francesco Cortiula retweeted
Important data.
‼️ Landmark #lungcancer research published today in Cell Scientists at the Francis Crick Institute and UCL have discovered a 14-protein blood signature that predicts lung cancer more than 5 years before diagnosis, works in never-smokers, and could identify who benefits from prevention treatment. People with high levels of these proteins were the ones who actually benefited from a drug to damp that inflammation down, cutting their lung cancer risk nearly in half. This could finally give us something lung cancer has never had: a way to prevent it in the people most at risk. doi.org/10.1016/j.cell.2026.… #LCSM
11
27
4,123
Francesco Cortiula retweeted
ANVIL: ADJ Nivolumab not ⬆️DFS vs BSC in IB/III NSCLC even in high PDL1 Heterogenous data with ADJ IO. No quality of surgery & good staging (PET/🧠) across trials. No tumor ➡️ADJ IO not work Do These negative results raise concerns about Role of ADJ after NEOADJ CTIO?#ASCO26
2
14
29
1,369
Pasi Janne presents overall survival by prognostic factors in FLAURA-2 trial of Osimertinib + chemo vs osi alone. Nicely summarized in his last slide. #ESMO25 #LCSM
2
40
1
116
7,992
Francesco Cortiula retweeted
ALEX trial 1st L alectinib (vs crizo) not ⬆️OS but trial not powered for OS. The best drug first? living w/o disease PD and good control of risk of brain PD count most!!Today lorlatinib is one SoC, futute SoC in 1st line Neladalkib (NVL655), ALKZAR trial vs alectinib?. #ESMO25
22
3
46
10,833
Francesco Cortiula retweeted
Zipalertinib in EGFRex20ins NSCLC reported 31% of intracranial ORR 🧠. Today crowded space of TKI for EGFRex20ins. New SoC? Best sequence? Brain activity and toxicity relevant for 1st Line decision. #ESMO25
30
79
4,173
Francesco Cortiula retweeted
Session opens with a case of stage IIIB #NSCLC in a frail 76-year-old. The MDT recommends sequential chemoradiotherapy. @FCortiula asks: ❓Can we de-escalate without losing radical intent? ❓Can immunotherapy reduce toxicity? ❓Can we tailor treatment to response? #ESMO25 #MedX
2
1
102
Francesco Cortiula retweeted
1
11
31
2,709
Discuss a wide range of case studies with leading experts! Access practical cancer IO insights at @sitcancer’s #virtual ACI: A Focus on Lung Cancers program Sept. 12. View topics: ow.ly/sn3c50WMRj5 @ChaftJamie @FCortiula @DrJNaidoo @drshieldsmd #LearnACI
3
5
744
Francesco Cortiula retweeted
Press release updates data for NVL-520, zidesamtinib, in #ROS1 NSCLC. In 117 pts who had prior TKI (half had 2+ TKIs), RR 44% with 78% ongoing after one year. Intracranial efficacy and active in ROS1 G2032R. Tolerability: discontinuation rate only 2%! investors.nuvalent.com/2025-…
16
1
50
3,448
Francesco Cortiula retweeted
📣Updated ESMO #ClinicalPracticeGuideline recommendations in oncogene-addicted metastatic #NSCLC: more #TargetedTherapy agents now available in 1L or at resistance. #LungCancer #mNSCLC #ESMOGuidelines 🔗 ow.ly/v7nE50Wbqsf
15
26
3,085
Francesco Cortiula retweeted
📣Updated ESMO #ClinicalPracticeGuideline recommendations in the non-oncogene-addicted metastatic #NSCLC: new 1L Tx options approved. 🔗 ow.ly/kzQF50Wa0lf #LungCancer #mNSCLC #ESMOGuidelines
18
2
37
7,787
Francesco Cortiula retweeted
#ASCO25 Developmental Therapeutics CSS🔥 Ph III DELLI trial: ultra-low dose nivo in 2L all solid tumors v chemo @VanitaNoronha @TataMemorial: - 500pts - OS HR 0.80 (p=0.02, NS primary endpt HR 0.75) - no diff in PFS/ORR/tox A brave trial, next step evaluate chemoIO? @asco
5
19
849
Why is CM816 so important? After @FordePatrick beautiful presentation of these revolutionary data, let’s dig into why this unique trial should shake up our vision for oncology research…
5
30
2
98
16,725
Francesco Cortiula retweeted
#ASCO25 Dr. @charlesrudin presents interim analysis of DeLLphi-304: randomized phase II study of tarlatamab (DLL3 TCE) vs 2L chemo in #SCLC. Chemo was mostly topotecan; 45% of pts were platinum resistant. Clear OS benefit with HR 0.60 (13.6m vs 8.3m). PFS 4.2 vs 3.7m, HR 0.71.
6
37
2
115
15,530
Francesco Cortiula retweeted
IMforte: lurbinectedin + atezo maintenance ES-SCLC ✅ ⬆️ mPFS 5.4 v 2.1m, HR 0.54 ✅ ⬆️ mOS 13.2 v 10.6m, HR 0.73 ✅ ⬆️ ORR 19% v 10% 🔺Gr3+ AE 25% v 5% 🔺 Myelosupression, N&V, fatigue 🤔 Active combo, at cost of toxicity 🤔 OS impressive = 16m from diagnosis #LCSM #ASCO25
14
31
2,777
Francesco Cortiula retweeted
Remarkable results in pretreated EGFR mutant lung cancer! In global trial, stellar benefit in progression-free survival for the addition of ivonescimab to platinum doublet chemo. Given tox profile may be a preferred option in this setting. #LCSM #ASCO25
3
6
1
38
6,618
Francesco Cortiula retweeted
Fascinating paper @NatureCancer on mechanisms of resistance to TIL in NSCLC: - serial multiomic analysis, 16pt TIL trial - subclonal neoAg lost at progression - LOH of pMHC in KRAS-specific Tcells at progression @BenCreelan @MoffittNews @OncoAlert #LCSM nature.com/articles/s43018-0…
2
19
1
67
4,692
Francesco Cortiula retweeted
In @JTOonline #BRAF-mutated #NSCLC: bit.ly/JTO_BRAF 📊 1L targeted therapy (dabrafenib/trametinib) vs. chemo-IO shows: ➖ Similar OS outcomes ➖ PD-L1 status & gender influence prognosis 🎯 Personalization > one-size-fits-all @LungCancerRx @oncodaily @OncBrothers
2
12
1
45
4,077
Francesco Cortiula retweeted
Personalised approach at osimertinib PD with savolitinib and osimertinib in MET deregulated EGFRm NSCLC looks promising. Is it better than CT+Ami or ADC? Hwr, it is a chemofree strategy and other treatments could be applied later #ELCC25
33
77
5,309